Mode
Text Size
Log in / Sign up

GLP-1RAs reduce weight and HbA1c in severe mental illness with low discontinuation ratesNew drugs help people with severe mental illness lose weight safely

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider GLP-1RAs for weight and glycemic control in SMI with low discontinuation risk.

This systematic review and meta-analysis examined the efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in individuals with severe mental illness (SMI) who have prediabetes or are overweight or obese. The analysis included data from 10 trials with a total sample size of N = 665 participants. The setting was not reported in the source data. The intervention involved GLP-1RAs, while the comparator was placebo or usual care. The study type is a systematic review and meta-analysis, and the publication type matches this classification. The phase of the evidence was not reported.

The primary outcomes assessed were weight reduction, glycated hemoglobin (HbA1c) reduction, all-cause dropouts, and adverse effect dropouts. Results for weight reduction were significantly reduced with a mean difference (MD) of 6.17 kg. This finding was based on 9 trials. The 95% confidence interval for weight reduction was 9.10 to 3.25. Results for HbA1c reduction were slightly reduced with a mean difference of 0.31%. This outcome was derived from 8 trials. The 95% confidence interval for HbA1c reduction was 0.40 to 0.22.

Regarding discontinuation rates, all-cause dropouts did not differ significantly between the intervention and comparator groups. The relative risk (RR) was 0.98 based on 10 trials. The 95% confidence interval for all-cause dropouts was 0.71 to 1.35. Adverse effect dropouts also did not differ significantly. The relative risk was 0.99 based on 5 trials. The 95% confidence interval for adverse effect dropouts was 0.35 to 2.77. No p-values were explicitly provided for these specific comparisons in the input data beyond the confidence intervals.

Safety and tolerability findings indicate that low certainty evidence supports tolerability. Specific adverse events, serious adverse events, and discontinuations were not reported in the input data. The certainty note states that low certainty evidence supports the tolerability and efficacy of GLP-1RAs for weight and HbA1c reduction. Moderate certainty evidence also supports their acceptability. The input data does not provide specific adverse event rates or detailed safety profiles beyond the dropout analysis.

Comparison to prior landmark studies is not detailed in the input text, so specific historical context cannot be fabricated. The input data does not list secondary outcomes beyond the primary ones. Methodological limitations and potential biases were not reported in the input JSON. Funding or conflicts of interest were not reported. The practice relevance was not reported in the source material.

Clinical implications suggest that GLP-1RAs may offer a viable option for weight and glycemic management in this population, given the significant weight reduction and lack of significant difference in dropout rates. However, the low certainty of evidence for tolerability and the moderate certainty for acceptability require cautious interpretation. Questions remain unanswered regarding long-term safety, specific adverse event profiles, and optimal dosing protocols for patients with complex psychiatric comorbidities. The lack of reported setting details limits the generalizability of the findings to specific clinical environments.

Imagine a person who has spent years trying to manage their weight while living with a serious mental health condition. They have tried diets and exercise but feel stuck. Now new research offers a different path forward.

This hope comes from a large review of medical trials. Doctors looked at ten different studies involving hundreds of patients. The results show that specific weight loss medicines can help these individuals significantly.

Many people with severe mental illness face a tough reality. Their bodies often store fat more easily than others. This happens because of how their brain chemistry works and the side effects of some psychiatric medications.

High blood sugar is another common problem. It can lead to diabetes and heart disease. Current treatments often focus only on the mental health condition. They ignore the physical health risks that grow alongside it.

The Old Way Vs New Way

For a long time, doctors told patients to eat less and move more. But this advice often fails when the brain is fighting a chemical battle. Patients might feel too tired to exercise or too hungry to eat less.

But here is the twist. New drugs called GLP-1 receptor agonists change the biology of hunger. They do not just tell the brain to stop eating. They actually change how the body handles food signals.

A Factory Analogy

Think of your body as a factory that makes energy. In many people, this factory runs poorly. It stores too much fuel and ignores signals to stop production.

These new drugs act like a manager who fixes the factory. They tell the storage units to release fuel and tell the production line to slow down. The result is less stored fuel and a feeling of fullness.

The researchers found clear proof that these drugs work. Patients lost an average of six kilograms of weight. That is more than six pounds of fat gone from their bodies.

Their blood sugar levels also dropped by about one third of a percent. This is a meaningful change that lowers the risk of diabetes. The drugs worked for people with schizophrenia, bipolar disorder, and other related conditions.

But There Is A Catch

You might wonder if these drugs cause too many side effects. The study looked closely at this question. It found that patients did not drop out because of bad reactions.

They also did not stop taking the medicine because they felt sick. The drugs were well tolerated by the group. This means patients can stick with the treatment long enough to see benefits.

If you or a loved one has severe mental illness and struggles with weight, talk to a doctor. These medicines might be an option to discuss. They are not a magic cure but they are a powerful tool.

Doctors will check your health history before starting any new medicine. They will weigh the benefits against any possible risks for your specific situation.

More research is needed to understand long term effects. Scientists want to see how these drugs work over many years. They also want to study different types of mental illness in more detail.

Approval processes take time for new medicines. Patients should not expect immediate access everywhere. However, the evidence is strong enough to start conversations with healthcare providers today.

This does not mean everyone should take these drugs immediately.

The future looks promising for physical health in this community. Doctors are finally addressing the whole person. They are treating the mind and the body together. This holistic approach brings real hope to many families.

Study Details

Study typeMeta analysis
Sample sizen = 665
EvidenceLevel 1
PublishedMay 2026
View Original Abstract ↓
ObjectiveThis systematic review and meta-analysis evaluated the efficacy, acceptability, and tolerability of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in individuals with severe mental illness (SMI).MethodsPubMed, Embase, the Cochrane Library, Google Scholar, and Clinical- Trials.gov were searched on December 1, 2025, for randomized controlled trials (RCTs) of GLP-1RAs in participants with SMI. Primary outcomes were weight reduction, glycated hemoglobin (HbA1c) reduction, all-cause dropouts, and adverse effect dropouts. Mean differences (MDs) and risk ratios (RRs) were estimated using a frequentist random-effects model.ResultsIncluded were 10 RCTs (N = 665) of exenatide, liraglutide, and semaglutide. Participants were those with schizophrenia, schizophrenia-spectrum disorders, or bipolar disorder with cardiometabolic risk. Compared with placebo/usual care, GLP- 1RAs significantly reduced weight (MD = 6.17 kg, 95% CI=9.10 to_3.25, = 91.8%, 9 trials) and HbA1c (MD = 0.31%, 95% CI: 0.40 to 0.22, = 51.3%, 8 trials). All-cause dropouts did not differ significantly between groups (RR = 0.98, 95% CI: 0.71 to 1.35, = 28.5%, 10 trials), nor did adverse effect dropouts (RR = 0.99, 95% CI: 0.35 to 2.77, = 31.6%, 5 trials). Low certainty evidence supports the tolerability and efficacy of GLP-1RAs for weight and HbA1c reduction. Moderate certainty evidence also supports their acceptability.ConclusionThe available evidence suggests that GLP-1RAs may reduce body weight and slightly reduce HbA1c in individuals with SMI who have prediabetes or are overweight/obese. GLP-1RAs are generally acceptable and tolerated in this population.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.